Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Our mission is to reduce the burden of glaucoma on patients and the healthcare system by providing innovative micro-invasive glaucoma surgery (MIGS) treatments that improve patient outcomes and reduce healthcare costs.

Our vision is to be the leader in ophthalmic micro-invasive glaucoma surgery (MIGS) devices and treatments that meaningfully improve patients' quality of life.

Glaukos has been recognized by the CNBC Upstart 100, received the 2017 Visionary Award from the Glaucoma Foundation and earned the Red Herring Top 100 Global Award in 2018.